Senti Biosciences
PublicSenti Biosciences is now publicly traded
The data on this page reflects Senti Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Convertible Debt
Jun 4, 2026
Total Funding Raised
$279.38M
Company Overview
Senti Bio is a biotechnology company specializing in the development of next-generation cell and gene therapies using innovative gene circuit platform technologies to combat difficult diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
Senti Biosciences Comparables
Compare Senti Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| A2 Biotherapeutics | 80% | |
| Wugen | 76% | |
| Cartherics | 74% |
Senti Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Jun 4, 2026 | ||||
| PIPE | Dec 5, 2024 | ||||
| Grant | Jun 1, 2024 | ||||
| Reverse Merger | Jun 8, 2022 | ||||
| Convertible Debt | May 19, 2022 | ||||
Series B | Jan 6, 2021 |
Senti Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Series B |
| Smilegate Investment | Series B |
| Nest.Bio | Series A, Series B |
| LifeSci Venture Partners | Series B |
| KB Investment | Series B |
| Omega Funds | Series A |
| Ridgeback Capital | Series B |
Senti Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access